190 related articles for article (PubMed ID: 22126567)
61. The effect of adjuvant chemotherapy on survival in Korean patients with node negative T1c, triple negative breast cancer.
Lim ST; Park CH; Kim SY; Nam SJ; Kang EY; Moon BI; Lee HJ; Jeon YW; Gwak H; Suh YJ
PLoS One; 2018; 13(5):e0197523. PubMed ID: 29768496
[TBL] [Abstract][Full Text] [Related]
62. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.
Joensuu H; Bono P; Kataja V; Alanko T; Kokko R; Asola R; Utriainen T; Turpeenniemi-Hujanen T; Jyrkkiö S; Möykkynen K; Helle L; Ingalsuo S; Pajunen M; Huusko M; Salminen T; Auvinen P; Leinonen H; Leinonen M; Isola J; Kellokumpu-Lehtinen PL
J Clin Oncol; 2009 Dec; 27(34):5685-92. PubMed ID: 19884557
[TBL] [Abstract][Full Text] [Related]
63. Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC).
Vulsteke C; Lambrechts D; Dieudonné A; Hatse S; Brouwers B; van Brussel T; Neven P; Belmans A; Schöffski P; Paridaens R; Wildiers H
Ann Oncol; 2013 Jun; 24(6):1513-25. PubMed ID: 23396606
[TBL] [Abstract][Full Text] [Related]
64. [Neoadjuvant chemotherapy for primary breast cancer].
Li JF; Ouyang T; Wang TF; Lin BY
Zhonghua Zhong Liu Za Zhi; 2004 Aug; 26(8):493-5. PubMed ID: 15555342
[TBL] [Abstract][Full Text] [Related]
65. Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study.
Martín M; Ruiz Simón A; Ruiz Borrego M; Ribelles N; Rodríguez-Lescure Á; Muñoz-Mateu M; González S; Margelí Vila M; Barnadas A; Ramos M; Del Barco Berron S; Jara C; Calvo L; Martínez-Jáñez N; Mendiola Fernández C; Rodríguez CA; Martínez de Dueñas E; Andrés R; Plazaola A; de la Haba-Rodríguez J; López-Vega JM; Adrover E; Ballesteros AI; Santaballa A; Sánchez-Rovira P; Baena-Cañada JM; Casas M; del Carmen Cámara M; Carrasco EM; Lluch A
J Clin Oncol; 2015 Nov; 33(32):3788-95. PubMed ID: 26416999
[TBL] [Abstract][Full Text] [Related]
66. Combination chemotherapy with cyclophosphamide, fluorouracil, and either epirubicin or mitoxantrone: a comparative randomized multicenter study in metastatic breast carcinoma.
Periti P; Pannuti F; Della Cuna GR; Mazzei T; Mini E; Martoni A; Preti P; Ercolino L; Pavesi L; Ribecco A
Cancer Invest; 1991; 9(3):249-55. PubMed ID: 1913227
[TBL] [Abstract][Full Text] [Related]
67. Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial.
Kerbrat P; Roché H; Bonneterre J; Veyret C; Lortholary A; Monnier A; Fumoleau P; Fargeot P; Namer M; Chollet P; Goudier MJ; Audhuy B; Simon H; Montcuquet P; Eymard JC; Walter S; Clavère P; Guastalla JP;
Br J Cancer; 2007 Jun; 96(11):1633-8. PubMed ID: 17505516
[TBL] [Abstract][Full Text] [Related]
68. A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer.
Robidoux A; Buzdar AU; Quinaux E; Jacobs S; Rastogi P; Fourchotte V; Younan RJ; Pajon ER; Shalaby IA; Desai AM; Fehrenbacher L; Geyer CE; Mamounas EP; Wolmark N
Clin Breast Cancer; 2010 Feb; 10(1):81-6. PubMed ID: 20133263
[TBL] [Abstract][Full Text] [Related]
69. Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study.
Ackland SP; Anton A; Breitbach GP; Colajori E; Tursi JM; Delfino C; Efremidis A; Ezzat A; Fittipaldo A; Kolaric K; Lopez M; Viaro D;
J Clin Oncol; 2001 Feb; 19(4):943-53. PubMed ID: 11181656
[TBL] [Abstract][Full Text] [Related]
70. Update results of FEC followed by docetaxel neoadjuvant trials for primary breast cancer.
Ohnoa S; Toi M; Kuroi K; Nakamura S; Iwata H; Kusama M; Masuda N; Yamazaki K; Hisamatsu K; Sato Y; Takatsuka Y; Shin E; Kaise H; Kurozumi M; Tsuda H; Akiyama F
Biomed Pharmacother; 2005 Oct; 59 Suppl 2():S323-4. PubMed ID: 16507401
[TBL] [Abstract][Full Text] [Related]
71. Weekly paclitaxel improved pathologic response of primary chemotherapy compared with standard 3 weeks schedule in primary breast cancer.
Qi M; Li JF; Xie YT; Lu AP; Lin BY; Ouyang T
Breast Cancer Res Treat; 2010 Aug; 123(1):197-202. PubMed ID: 20582466
[TBL] [Abstract][Full Text] [Related]
72. Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology).
Geyer CE; Bandos H; Rastogi P; Jacobs SA; Robidoux A; Fehrenbacher L; Ward PJ; Polikoff J; Brufsky AM; Provencher L; Paterson AHG; Hamm JT; Carolla RL; Baez-Diaz L; Julian TB; Swain SM; Mamounas EP; Wolmark N
Breast Cancer Res Treat; 2022 Jun; 193(3):555-564. PubMed ID: 35230585
[TBL] [Abstract][Full Text] [Related]
73. Quality of life in women with breast cancer during the first year after random assignment to adjuvant treatment with marrow-supported high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin or tailored therapy with Fluorouracil, epirubicin, and cyclophosphamide: Scandinavian Breast Group Study 9401.
Brandberg Y; Michelson H; Nilsson B; Bolund C; Erikstein B; Hietanen P; Kaasa S; Nilsson J; Wiklund T; Wilking N; Bergh J;
J Clin Oncol; 2003 Oct; 21(19):3659-64. PubMed ID: 14512398
[TBL] [Abstract][Full Text] [Related]
74. Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies.
Lambertini M; Ceppi M; Cognetti F; Cavazzini G; De Laurentiis M; De Placido S; Michelotti A; Bisagni G; Durando A; Valle E; Scotto T; De Censi A; Turletti A; Benasso M; Barni S; Montemurro F; Puglisi F; Levaggi A; Giraudi S; Bighin C; Bruzzi P; Del Mastro L;
Eur J Cancer; 2017 Jan; 71():34-42. PubMed ID: 27951450
[TBL] [Abstract][Full Text] [Related]
75. [Retrospective analysis of dose intensity of epirubicin in breast cancer].
Konecny G; Frank M; Kahlert S; Untch M; Hepp H
Gynakol Geburtshilfliche Rundsch; 2000; 40(3-4):145-52. PubMed ID: 11326159
[TBL] [Abstract][Full Text] [Related]
76. The Canadian experience with intensive fluorouracil, epirubicin and cyclophosphamide in patients with early stage breast cancer.
Levine MN; Bramwell V; Pritchard K; Perrault D; Findlay B; Abu-Zahra H; Warr D; Arnold A; Skillings J
Drugs; 1993; 45 Suppl 2():51-9; discussion 58-9. PubMed ID: 7693423
[TBL] [Abstract][Full Text] [Related]
77. [The feasibility of CEF (cyclophosphamide, epirubicin, 5-FU) regimen in the adjuvant setting of primary breast cancer].
Honda S; Toi M; Shimizu S; Hayashi K; Tominaga T
Gan To Kagaku Ryoho; 1997 Apr; 24(6):679-83. PubMed ID: 9126304
[TBL] [Abstract][Full Text] [Related]
78. [Efficacy of neoadjuvant chemotherapy with FEC and TEC regimen on breast cancer].
Wang B; Fu JF; Hong ZW
Ai Zheng; 2009 Mar; 28(3):292-6. PubMed ID: 19619445
[TBL] [Abstract][Full Text] [Related]
79. Feasibility of two dose-dense FEC regimens with growth factor support for adjuvant therapy in patients with early breast cancer: results from a randomised study of the Central European Cooperative Oncology Group (CECOG).
Kahán Z; Spanik S; Wagnerova M; Skacel T; Planko B; Fitzthum E; Lindner E; Soldatenkova V; Zielinski CC; Brodowicz T
Breast Cancer Res Treat; 2008 Dec; 112(3):557-63. PubMed ID: 18189160
[TBL] [Abstract][Full Text] [Related]
80. Leukocyte nadir as a predictive factor for efficacy of adjuvant chemotherapy in breast cancer. Results from the prospective trial SBG 2000-1.
Poikonen-Saksela P; Lindman H; Sverrisdottir A; Edlund P; Villman K; Tennvall Nittby L; Cold S; Bechmann T; Stenbygaard L; Ejlertsen B; Andersson M; Blomqvist C; Bergh J; Ahlgren J
Acta Oncol; 2020 Jul; 59(7):825-832. PubMed ID: 32347139
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]